Compound ID | 3390
APT Phagebank
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Direct acting; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Target Pathogen: | Active against Staphylococcus aureus and Pseudomonas aeruginosa |
| Institute where first reported: | Adaptive Phage Therapeutics |
| Year first mentioned: | 2022 |
| Highest developmental phase: | Phase 2 (NCT05269121) |
| Development status: | Inactive |
| Reason Dropped: | Withdrawn by sponsors; reason unclear |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.